Neustart mit "frischem Kapital"
20.12.18 14:28
#128
martin30sm
News
Gilead And Agenus Enter into Collaboration to Develop Immuno-Oncology Therapies
-- Agenus Webcast and Conference Call Scheduled for Today at 8:30a.m.ET --
FOSTER CITY, Calif. and LEXINGTON, Mass., Dec. 20, 2018 /PRNewswire/ -- Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five novel immuno-oncology therapies.
Agenus Logo
Under the terms of the agreement, Agenus will receive $150 million upon closing, which includes a $120 million upfront cash payment and a $30 million equity investment. The agreement also includes approximately $1.7 billion in potential future fees and milestones. Gilead will receive worldwide exclusive rights to AGEN1423, which has an estimated IND filing by year-end 2018. Gilead will also receive the exclusive option to license two additional programs: AGEN1223 and AGEN2373. Agenus has filed the IND for AGEN1223 and has a planned IND filing for AGEN2373 in the first half of 2019. Agenus will be responsible for developing the option programs up to the option decision points, at which time Gilead may acquire exclusive rights to the programs on option exercise. For one of the option programs, Agenus will have the right to opt-in to shared development and commercialization in the U.S. Gilead will also receive right of first negotiation for two additional, undisclosed preclinical programs.
"Recent advances in immuno-oncology have produced unprecedented benefit to patients; however, many people with cancer still require more effective treatment options," said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. "Our collaboration with Agenus gives us access to novel and differentiated immune modulating antibodies that will complement our growing oncology portfolio and cell therapy business. We look forward to partnering with the Agenus team."
"Gilead is an ideal partner for Agenus for the rapid advancement of our pipeline," said Garo Armen, PhD, Chairman and CEO, Agenus. "By year end, our discovery platforms will have resulted in six INDs in 2018 and 13 INDs by the 1H2019. Gilead's established global presence and commitment to disruptive therapies, combined with our track-record in building a broad pipeline in I-O, has the potential to yield breakthrough I-O treatments for patients with cancer."
This transaction is subject to clearance under the Hart-Scott Rodino Antitrust Improvements Act and other customary closing conditions.
AGEN1423, AGEN1223 and AGEN2373 are investigational agents that have not been approved for any uses. Efficacy and safety have not been established.
Agenus Conference Call Information:
Date: Thursday, December 20, 2018
Time: 8:30 a.m. ET
Domestic Dial-in Number: 1-844-492-3727
International Dial-in Number: 1-412-317-5118
Conference ID: Agenus call
The presentation will be webcast live and may be accessed by visiting the "Events & Presentations" page within the Investors section of the Agenus website at agenusbio.com or by using the link below. A replay of the webcast will be available on the Agenus website following the conference.
Webcast link: https://www.webcaster4.com/Webcast/Page/1556/28871
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company's website at www.gilead.com.
Agenus Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the anticipated closing and expected benefits of the collaboration, as well as timing for planned IND filings. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Gilead Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the ability of the parties to complete this transaction in a timely manner or at all, the ability of the parties to file the anticipated INDs for AGEN1423 and AGEN2373 and meet potential milestones in the estimated timelines or at all and the risk that the parties may not realize the expected benefits of this collaboration. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
Gilead Contacts:
Agenus Contact:
Sung Lee, Investors
Jennifer Buell, PhD,
(650) 524-7792
Investors
781-674-4420
Nathan Kaiser, Media
Jennifer.Buell@agenusbio.com
(650) 522-1853
Olivia Mullane,
Media
212-715-1597
SOURCE Agenus
-- Agenus Webcast and Conference Call Scheduled for Today at 8:30a.m.ET --
FOSTER CITY, Calif. and LEXINGTON, Mass., Dec. 20, 2018 /PRNewswire/ -- Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc. (NASDAQ: AGEN) announced today the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five novel immuno-oncology therapies.
Agenus Logo
Under the terms of the agreement, Agenus will receive $150 million upon closing, which includes a $120 million upfront cash payment and a $30 million equity investment. The agreement also includes approximately $1.7 billion in potential future fees and milestones. Gilead will receive worldwide exclusive rights to AGEN1423, which has an estimated IND filing by year-end 2018. Gilead will also receive the exclusive option to license two additional programs: AGEN1223 and AGEN2373. Agenus has filed the IND for AGEN1223 and has a planned IND filing for AGEN2373 in the first half of 2019. Agenus will be responsible for developing the option programs up to the option decision points, at which time Gilead may acquire exclusive rights to the programs on option exercise. For one of the option programs, Agenus will have the right to opt-in to shared development and commercialization in the U.S. Gilead will also receive right of first negotiation for two additional, undisclosed preclinical programs.
"Recent advances in immuno-oncology have produced unprecedented benefit to patients; however, many people with cancer still require more effective treatment options," said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. "Our collaboration with Agenus gives us access to novel and differentiated immune modulating antibodies that will complement our growing oncology portfolio and cell therapy business. We look forward to partnering with the Agenus team."
"Gilead is an ideal partner for Agenus for the rapid advancement of our pipeline," said Garo Armen, PhD, Chairman and CEO, Agenus. "By year end, our discovery platforms will have resulted in six INDs in 2018 and 13 INDs by the 1H2019. Gilead's established global presence and commitment to disruptive therapies, combined with our track-record in building a broad pipeline in I-O, has the potential to yield breakthrough I-O treatments for patients with cancer."
This transaction is subject to clearance under the Hart-Scott Rodino Antitrust Improvements Act and other customary closing conditions.
AGEN1423, AGEN1223 and AGEN2373 are investigational agents that have not been approved for any uses. Efficacy and safety have not been established.
Agenus Conference Call Information:
Date: Thursday, December 20, 2018
Time: 8:30 a.m. ET
Domestic Dial-in Number: 1-844-492-3727
International Dial-in Number: 1-412-317-5118
Conference ID: Agenus call
The presentation will be webcast live and may be accessed by visiting the "Events & Presentations" page within the Investors section of the Agenus website at agenusbio.com or by using the link below. A replay of the webcast will be available on the Agenus website following the conference.
Webcast link: https://www.webcaster4.com/Webcast/Page/1556/28871
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.
About Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company's website at www.gilead.com.
Agenus Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the anticipated closing and expected benefits of the collaboration, as well as timing for planned IND filings. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Gilead Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the ability of the parties to complete this transaction in a timely manner or at all, the ability of the parties to file the anticipated INDs for AGEN1423 and AGEN2373 and meet potential milestones in the estimated timelines or at all and the risk that the parties may not realize the expected benefits of this collaboration. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
Gilead Contacts:
Agenus Contact:
Sung Lee, Investors
Jennifer Buell, PhD,
(650) 524-7792
Investors
781-674-4420
Nathan Kaiser, Media
Jennifer.Buell@agenusbio.com
(650) 522-1853
Olivia Mullane,
Media
212-715-1597
SOURCE Agenus
20.12.18 15:50
#131
Senseo2016
Die Fonds werden erst wieder ab 7.1.19
aktiv - bin dahin sollte man sich hier eindecken . Gilead gibt nicht umsonst 120 Mio Cash
20.12.18 16:21
#132
Vassago
AGEN 2,68$ (+33%)
Deal mit Gilead
- 120 Mio. $ Upfront Cash payment
https://endpts.com/...self-a-generous-partner-in-gilead-shares-surge/
20.12.18 16:36
#133
Senseo2016
Wer Gilead noch nicht kennen sollte
Angehängte Grafik:
bildschirmfoto_2018-12-20_um_16.png (verkleinert auf 30%)
bildschirmfoto_2018-12-20_um_16.png (verkleinert auf 30%)
20.12.18 19:29
#139
Senseo2016
138 Richy
Mal sehen ob die noch kommen Richy. Bei dem Marktumfeld sind wir morgen eher wieder bei 2 $
Schade um die tolle Meldung
Schade um die tolle Meldung
20.12.18 20:04
#140
Senseo2016
So schnell wird man trotz guter News
eiskalt ausgestoppt - schade - wünsche dem Rest alles Gute
21.12.18 08:41
#141
iTechDachs
In 'normalen' Zeiten wären auch 10 Dollar
locker drin gewesen. Immerhin rund 25% im Plus bei $2.50 gehalten.
21.12.18 10:23
#143
RichyBerlin
AGEN
Also den 10$ kann ich nur zustimmen.
Agenus hat sich mit den 120Mio.Cash viel Luft verschafft. Und die 30Mio Equity verdeutlichen die Ernsthaftigkeit der Sache nochmal. Die 1,7 Mrd.Biobucks jetzt mal außer Acht gelassen.
Charttechnisch sind die 10$ sowieso kein Problem, sondern eher etwas was schon länger möglich war. Die Marktkapi ist unter 300 Mio.$, also echt Peanuts für US-Verhältnisse.
In 2019 auf jeden Fall dran bleiben, auch wenn gerade die Medigener unter uns leidvoll erfahren haben wie sich jahrelanges Schweigen nach einem tollen Deal dann irgendwann negativ im Kurs auswirkt..
Vielleicht machen Agenus/Gilead es ja besser
Agenus hat sich mit den 120Mio.Cash viel Luft verschafft. Und die 30Mio Equity verdeutlichen die Ernsthaftigkeit der Sache nochmal. Die 1,7 Mrd.Biobucks jetzt mal außer Acht gelassen.
Charttechnisch sind die 10$ sowieso kein Problem, sondern eher etwas was schon länger möglich war. Die Marktkapi ist unter 300 Mio.$, also echt Peanuts für US-Verhältnisse.
In 2019 auf jeden Fall dran bleiben, auch wenn gerade die Medigener unter uns leidvoll erfahren haben wie sich jahrelanges Schweigen nach einem tollen Deal dann irgendwann negativ im Kurs auswirkt..
Vielleicht machen Agenus/Gilead es ja besser
Angehängte Grafik:
agen_2018-12-20.jpg (verkleinert auf 22%)
agen_2018-12-20.jpg (verkleinert auf 22%)
21.12.18 11:28
#144
RichyBerlin
Endpoints incl.Brad Loncar
https://endpts.com/...nerous%20partner%20in%20Gilead%20shares%20surge
03.01.19 22:15
#148
martin30sm
News
Agenus Awarded Grant to Enable QS-21 Innovations
- Bill & Melinda Gates Foundation invests ~$1M to develop novel technology for QS-21
- Grant to develop an alternative, novel plant cell-culture based method for QS-21 production
LEXINGTON, Massachusetts, Jan. 3, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today that the Bill & Melinda Gates Foundation awarded it a grant of ~$1M to develop an alternative, plant cell culture-based manufacturing process to ensure the continuous future supply of Agenus' proprietary QS-21 Stimulon adjuvant, a key component of multiple vaccines targeting infectious and endemic diseases.
Agenus Logo
Agenus' QS-21 Stimulon is a proprietary adjuvant, currently incorporated as part of Glaxo Smith Kline's (GSK's) highly efficacious Shingrix vaccine. Additionally, Agenus' QS-21 Stimulon is used in GSK's Mosquirix vaccine and numerous other clinical-stage vaccines, including Agenus' own cancer vaccines. Given the criticality of QS-21 in making vaccines efficacious, Agenus plans to develop a cell-culture based, environment friendly manufacturing technique as an alternative future supply. QS-21 is currently extracted from Chilean soap bark trees, exclusively sourced from a localized area in Chile.
"We are delighted to be working in partnership with the Bill & Melinda Gates Foundation in our efforts to revolutionize the way we produce QS-21," said Dr. Garo Armen, Chairman and CEO of Agenus. "The Gates Foundation has recognized the value of consistent supply of high-quality QS-21 to power vaccines. We appreciate their commitment to bringing innovation to drive access to important therapies."
The alternative manufacturing process for QS-21 will be developed in an exclusive partnership with Phyton Biotech2, a company with extensive experience developing and applying green chemistry solutions for the production of high-value phytochemicals. Leveraging its Plant Cell Fermentation (PCF) technology, Phyton Biotech will attempt to demonstrate that PCF is a feasible model for the consistent, large-scale and low-cost commercial production of high-quality QS-21 directly from plant cell cultures.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.
About Phyton Biotech
Phyton Biotech, a wholly-owned subsidiary of DFB Pharmaceuticals, is the global leader in Plant Cell Fermentation (PCF) Technology, offering comprehensive services for the development and commercialization of plant-based molecules, extracts and recombinant products, serving the pharmaceutical, Chinese Traditional Medicine, cosmetic, agricultural and food ingredient industries. Using PCF, Phyton Biotech offers a time, risk and cost-balanced path to commercially viable production processes, overcoming limitations often experienced with traditional plant extraction and chemical synthesis. As a biotechnology leader with certified GMP facilities in Germany and Canada, Phyton Biotech has a successful track record of developing and implementing innovative contract development solutions for clients around the world. The company is globally recognized for revolutionizing the manufacturing process for Paclitaxel from plant cell cultures using PCF. Phyton Biotech is now the world's largest producer of Paclitaxel and Docetaxel via PCF, with the capacity to meet more than one-third of the global demand for these critical active pharmaceutical ingredients. More info: phytonbiotech.com.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus' plans to develop a cell-culture based, environment friendly manufacturing technique as an alternative method to produce QS-21 in partnership with Phyton and the Bill & Melinda Gates Foundation. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Contacts:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
Phyton Biotech
Alex Russell
604-562-9262
alex@russellstrategy.com
1 Through AgenTus Therapeutics, a subsidiary of Agenus
2 Phyton Biotech will receive funding directly from Agenus to perform these services.
Logo - https://mma.prnewswire.com/media/403578/Agenus_Logo.jpg
© 2019 PR Newswire
- Bill & Melinda Gates Foundation invests ~$1M to develop novel technology for QS-21
- Grant to develop an alternative, novel plant cell-culture based method for QS-21 production
LEXINGTON, Massachusetts, Jan. 3, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, announced today that the Bill & Melinda Gates Foundation awarded it a grant of ~$1M to develop an alternative, plant cell culture-based manufacturing process to ensure the continuous future supply of Agenus' proprietary QS-21 Stimulon adjuvant, a key component of multiple vaccines targeting infectious and endemic diseases.
Agenus Logo
Agenus' QS-21 Stimulon is a proprietary adjuvant, currently incorporated as part of Glaxo Smith Kline's (GSK's) highly efficacious Shingrix vaccine. Additionally, Agenus' QS-21 Stimulon is used in GSK's Mosquirix vaccine and numerous other clinical-stage vaccines, including Agenus' own cancer vaccines. Given the criticality of QS-21 in making vaccines efficacious, Agenus plans to develop a cell-culture based, environment friendly manufacturing technique as an alternative future supply. QS-21 is currently extracted from Chilean soap bark trees, exclusively sourced from a localized area in Chile.
"We are delighted to be working in partnership with the Bill & Melinda Gates Foundation in our efforts to revolutionize the way we produce QS-21," said Dr. Garo Armen, Chairman and CEO of Agenus. "The Gates Foundation has recognized the value of consistent supply of high-quality QS-21 to power vaccines. We appreciate their commitment to bringing innovation to drive access to important therapies."
The alternative manufacturing process for QS-21 will be developed in an exclusive partnership with Phyton Biotech2, a company with extensive experience developing and applying green chemistry solutions for the production of high-value phytochemicals. Leveraging its Plant Cell Fermentation (PCF) technology, Phyton Biotech will attempt to demonstrate that PCF is a feasible model for the consistent, large-scale and low-cost commercial production of high-quality QS-21 directly from plant cell cultures.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the discovery and development of therapies that engage the body's immune system to fight cancer. The Company's vision is to expand the patient populations benefiting from cancer immunotherapy by pursuing combination approaches that leverage a broad repertoire of antibody therapeutics, proprietary cancer vaccine platforms, and adoptive cell therapies (through its AgenTus Therapeutics subsidiary). The Company is equipped with a suite of antibody discovery platforms and a state-of-the-art GMP manufacturing facility with the capacity to support early phase clinical programs. Agenus is headquartered in Lexington, MA. For more information, please visit www.agenusbio.com and our twitter handle @agenus_bio. Information that may be important to investors will be routinely posted on our website and twitter.
About Phyton Biotech
Phyton Biotech, a wholly-owned subsidiary of DFB Pharmaceuticals, is the global leader in Plant Cell Fermentation (PCF) Technology, offering comprehensive services for the development and commercialization of plant-based molecules, extracts and recombinant products, serving the pharmaceutical, Chinese Traditional Medicine, cosmetic, agricultural and food ingredient industries. Using PCF, Phyton Biotech offers a time, risk and cost-balanced path to commercially viable production processes, overcoming limitations often experienced with traditional plant extraction and chemical synthesis. As a biotechnology leader with certified GMP facilities in Germany and Canada, Phyton Biotech has a successful track record of developing and implementing innovative contract development solutions for clients around the world. The company is globally recognized for revolutionizing the manufacturing process for Paclitaxel from plant cell cultures using PCF. Phyton Biotech is now the world's largest producer of Paclitaxel and Docetaxel via PCF, with the capacity to meet more than one-third of the global demand for these critical active pharmaceutical ingredients. More info: phytonbiotech.com.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding Agenus' plans to develop a cell-culture based, environment friendly manufacturing technique as an alternative method to produce QS-21 in partnership with Phyton and the Bill & Melinda Gates Foundation. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Contacts:
Agenus Inc.
Jennifer Buell, PhD
781-674-4420
Jennifer.Buell@agenusbio.com
Phyton Biotech
Alex Russell
604-562-9262
alex@russellstrategy.com
1 Through AgenTus Therapeutics, a subsidiary of Agenus
2 Phyton Biotech will receive funding directly from Agenus to perform these services.
Logo - https://mma.prnewswire.com/media/403578/Agenus_Logo.jpg
© 2019 PR Newswire